Here is an opportunity to share your suggestions on how the FDA can improve their current opaque transparency policy. A second public meeting will be held November 3, 2009 from 9 a.m. to 3 p.m. at the National Transportation Safety Board Conference Center at 429 L'Enfant Plaza, SW, Washington, DC 20594. The three discussion groups are:

(1) Emerging safety issues concerning FDA-regulated products. What principles the FDA should employ in deciding whether to issue an early communication about a potential problem with an FDA-regulated product;

(2) Product applications that are abandoned or withdrawn by the applicant before approval. What principles FDA should employ regarding disclosure of data contained in abandoned or withdrawn product applications; and

(3) Communicating agency decisions about pending product applications. What information regarding pending product applications should be disclosed?

If you are interested in attending, you must register by October 27, 2009 (transparency.meeting@fda.hhs.gov). You can also submit electronic or written comments by November 6, 2009.

To submit electronic comments please use the web form below, or to submit written comments please send to: Division of Dockets Management (HFA-305), Food & Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

ANH-USA will attend and actively participate in one of the discussion panels as well as provide written comments for the remaining two panels.

Click here to take action.

As always, thank you for being involved!

Source: American Association for Health Freedom